» Articles » PMID: 12432234

Repeated DNA Vaccinations Elicited Qualitatively Different Cytotoxic T Lymphocytes and Improved Protective Antitumor Effects

Overview
Journal J Biomed Sci
Publisher Biomed Central
Specialty Biology
Date 2002 Nov 15
PMID 12432234
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The use of DNA vaccines for generating antigen-specific CD8+ T cell responses has been well established. However, little is known about the quantitative and qualitative aspects of CD8+ T cell responses and protective immunity generated after repeated DNA vaccinations. We used human papillomavirus (HPV) type-16 E7 as a model tumor antigen in an E7-expressing tumor model, TC-1, to assess the influence of the frequency of DNA vaccinations on E7-specific immunological and antitumor responses. Mice were vaccinated with 1-4 inoculations of pcDNA 3-E7 DNA. Immunological assays and tumor protection experiments were performed to assess the effect of repeated E7 DNA vaccination on E7-specific T cells and E7-expressing tumors. Our results demonstrated that mice receiving an increased number of E7 DNA vaccinations exhibited higher E7-specific CTL activity, a rapid expansion of E7-specific IFN-gamma-secreting CD8+ T cells upon stimulation with E7 antigen, and a stronger antitumor effect against an E7-expressing tumor. Furthermore, we found that increasing the number of E7 DNA vaccinations followed by vaccinia booster enhanced the functional avidity of E7-specific CD8+ T cells. Our data suggest that quantitative and qualitative characteristics of antigen-specific CD8 + T cell responses and the ensuing protective antitumor effect can be influenced by the frequency of DNA vaccinations. These results have important clinical implications for the use of naked DNA vaccines in cancer immunotherapy.

Citing Articles

A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins.

Panahi H, Bolhassani A, Javadi G, Noormohammadi Z PLoS One. 2018; 13(10):e0205933.

PMID: 30356257 PMC: 6200245. DOI: 10.1371/journal.pone.0205933.


Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009 - present).

Landis-Piwowar K, Chen D, Foldes R, Chan T, Dou Q Expert Opin Ther Pat. 2012; 23(2):189-202.

PMID: 23230990 PMC: 3840390. DOI: 10.1517/13543776.2013.743993.


The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine.

Wei H, Wu A, Hsu C, Lin Y, Cheng W, Su C Mol Ther. 2011; 19(12):2249-57.

PMID: 21792181 PMC: 3242654. DOI: 10.1038/mt.2011.152.


Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.

Chen C, Ho C, Chang M, Sun W, Chen Y, Chiang Y Mol Ther. 2010; 18(6):1233-43.

PMID: 20372107 PMC: 2889744. DOI: 10.1038/mt.2010.34.


Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.

Brandsma J, Shlyankevich M, Su Y, Zelterman D, Rose J, Buonocore L Vaccine. 2009; 28(52):8345-51.

PMID: 19615481 PMC: 2891918. DOI: 10.1016/j.vaccine.2009.04.082.